Therapeutic Drug Levels to Achieve Good Eular Response in Patients with Rheumatoid Arthritis Receiving Adalimumab: Results From the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (braggss) Cohort

RM Hum; P. Ho; N Nair; D Plant; A Morgan; J Isaacs; A. G. Wilson; K Hyrich; A Barton

doi:10.1136/annrheumdis-2022-eular.2338

Therapeutic Drug Levels to Achieve Good Eular Response in Patients with Rheumatoid Arthritis Receiving Adalimumab: Results From the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (braggss) Cohort

RM Hum, P. Ho, N Nair, D Plant, A Morgan, J Isaacs, A. G. Wilson, K Hyrich, A Barton

Division of Musculoskeletal & Dermatological Sciences (L5)

Research output: Contribution to conference › Abstract

Original language	English
Pages	1297-1298
Number of pages	2
DOIs	https://doi.org/10.1136/annrheumdis-2022-eular.2338
Publication status	Published - Jun 2022

Access to Document

10.1136/annrheumdis-2022-eular.2338

Cite this

Hum, RM., Ho, P., Nair, N., Plant, D., Morgan, A., Isaacs, J., Wilson, A. G., Hyrich, K., & Barton, A. (2022). Therapeutic Drug Levels to Achieve Good Eular Response in Patients with Rheumatoid Arthritis Receiving Adalimumab: Results From the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (braggss) Cohort. 1297-1298. https://doi.org/10.1136/annrheumdis-2022-eular.2338

@conference{10fd0f8a72eb42aa967e779dbae2fe92,

title = "Therapeutic Drug Levels to Achieve Good Eular Response in Patients with Rheumatoid Arthritis Receiving Adalimumab: Results From the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (braggss) Cohort",

author = "RM Hum and P. Ho and N Nair and D Plant and A Morgan and J Isaacs and Wilson, \{A. G.\} and K Hyrich and A Barton",

year = "2022",

month = jun,

doi = "10.1136/annrheumdis-2022-eular.2338",

language = "English",

pages = "1297--1298",

}

Hum, RM, Ho, P, Nair, N, Plant, D, Morgan, A, Isaacs, J, Wilson, AG, Hyrich, K & Barton, A 2022, 'Therapeutic Drug Levels to Achieve Good Eular Response in Patients with Rheumatoid Arthritis Receiving Adalimumab: Results From the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (braggss) Cohort', pp. 1297-1298. https://doi.org/10.1136/annrheumdis-2022-eular.2338

TY - CONF

T1 - Therapeutic Drug Levels to Achieve Good Eular Response in Patients with Rheumatoid Arthritis Receiving Adalimumab

T2 - Results From the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (braggss) Cohort

AU - Hum, RM

AU - Ho, P.

AU - Nair, N

AU - Plant, D

AU - Morgan, A

AU - Isaacs, J

AU - Wilson, A. G.

AU - Hyrich, K

AU - Barton, A

PY - 2022/6

Y1 - 2022/6

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pure_starter&SrcAuth=WosAPI&KeyUT=WOS:000850279005203&DestLinkType=FullRecord&DestApp=WOS

U2 - 10.1136/annrheumdis-2022-eular.2338

DO - 10.1136/annrheumdis-2022-eular.2338

M3 - Abstract

SP - 1297

EP - 1298

ER -

Therapeutic Drug Levels to Achieve Good Eular Response in Patients with Rheumatoid Arthritis Receiving Adalimumab: Results From the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (braggss) Cohort

Access to Document

Other files and links

Cite this